Targeting Protein Kinase C‐alpha (PKC‐α) in Cancer with the Phosphorothioate Antisense Oligonucleotide Aprinocarsen
- 1 December 2003
- journal article
- clinical trial
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1002 (1) , 263-270
- https://doi.org/10.1196/annals.1281.029
Abstract
Antisense oligonucleotides (ASOs) offer a novel pharmacological platform to develop highly specific drugs. As shown by the clinical development of aprinocarsen, an ASO directed against protein kinase C-alpha (PKC-alpha), this platform has made a remarkable advance from the bench to the bedside. This review summarizes the rationale of the early development of aprinocarsen and current clinical experience.Keywords
This publication has 15 references indexed in Scilit:
- The Potential Role of PKC β in Diabetic Retinopathy and Macular EdemaSurvey of Ophthalmology, 2002
- The Role of Environmental Carcinogens, Viruses, and GeneticCancer Biology & Therapy, 2002
- Protein kinase C inhibitorsCurrent Oncology Reports, 2002
- Toxicity of Antisense OligonucleotidesPublished by Taylor & Francis ,2001
- A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotidesPublished by Elsevier ,1999
- Directed antisense therapy confirms the role of protein kinase C–α in the tumorigenicity of pancreatic cancerSurgery, 1998
- Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-αCancer Letters, 1998
- Regulation of protein kinase C and role in cancer biologyCancer and Metastasis Reviews, 1994
- The potential of protein kinase C as A target for anticancer treatmentPharmacology & Therapeutics, 1993
- The molecular heterogeneity of protein kinase C and its implications for cellular regulationNature, 1988